A month after exiting from the microarray manufacturing sector, Incyte has signaled its intention to move further into the pharmaceutical arena by appointing a pair of big pharma executives to top positions. Paul Friedman, the former president of DuPont Pharmaceuticals Research Laboratories, is the new chief executive officer, replacing Roy Whitfield. Robert Stein, DuPont Pharmaceuticals’ former executive vice president of research and preclinical development, will serve as president and chief scientific officer.